Fulyzaq is supplied as delayed-release tablets for oral administration. It is crucial to follow the prescribed dosage and administration instructions carefully for optimal effectiveness.

• Dosage: The recommended dose of Fulyzaq is one 125 mg delayed-release tablet taken orally two times a day (BID).
• With or Without Food: Fulyzaq tablets can be taken with or without food, providing flexibility for patients.
• Swallow Whole: Fulyzaq tablets should not be crushed or chewed. They are delayed-release tablets, meaning they have a special coating designed to protect the medication until it reaches the intestines, where it is meant to be absorbed. Crushing or chewing the tablet would compromise this coating and could alter the drug’s effectiveness or lead to stomach upset.
• Consistency is Key: For consistent relief of diarrhea symptoms, it is important to take Fulyzaq regularly as prescribed by your doctor.
• Missed Dose: If a dose is missed, take the next scheduled dose at the regular time. Do not take two doses at the same time to make up for a missed dose.
• Duration of Treatment: Fulyzaq is intended for symptomatic relief of chronic non-infectious diarrhea in HIV/AIDS patients. The duration of treatment will be determined by your healthcare provider based on your response and ongoing need.

Fulyzaq (crofelemer) employs a distinct mechanism of action to alleviate secretory diarrhea without affecting gut motility. This mechanism targets specific channels responsible for fluid secretion in the intestines.

• Dual Ion Channel Inhibition: The primary mechanism of action for crofelemer is the inhibition of two key chloride ion channels located on the luminal side of the gastrointestinal tract:
  • Cystic Fibrosis Transmembrane Conductance Regulator (CFTR): This channel is responsible for secreting chloride ions into the intestinal lumen.
  • Calcium-Activated Chloride Channel (CaCC): This channel also contributes to chloride and fluid secretion.
  • By inhibiting both CFTR and CaCC, crofelemer reduces the secretion of chloride ions into the gut. This reduction in chloride secretion subsequently decreases the associated movement of sodium ions and water into the intestinal lumen.
• Antisecretory Effect: The net effect of this inhibition is a decrease in the amount of water and electrolytes secreted into the intestines, leading to improved stool consistency and a reduction in the frequency of watery bowel movements.
• No Impact on Gut Motility: A crucial aspect of Fulyzaq’s mechanism is that it does not affect gastrointestinal motility. This differentiates it from traditional anti-motility anti-diarrheals (like loperamide or diphenoxylate) that work by slowing down bowel movements, which can sometimes lead to issues like constipation.
• Minimal Systemic Absorption: Crofelemer is minimally, if at all, absorbed into the bloodstream from the gut. This means its action is primarily localized to the gastrointestinal tract, contributing to its favorable systemic safety profile and reducing the potential for systemic drug interactions.

In essence, Fulyzaq tackles the problem of secretory diarrhea by directly addressing the excessive fluid secretion in the intestines, offering a targeted and unique approach for relief.

While Fulyzaq is generally well-tolerated, like all medications, it can cause side effects. Most commonly reported side effects are generally mild and transient.

• Common Side Effects (occurring in 3% of patients and at a rate greater than placebo in clinical studies):
  • Upper respiratory tract infection
  • Bronchitis
  • Cough
  • Flatulence (gas)
  • Increased bilirubin (a liver enzyme, typically mild and not clinically significant)
  • Nausea
  • Back pain
  • Arthralgia (joint pain)
  • Urinary tract infection
  • Nasopharyngitis (common cold symptoms)
  • Musculoskeletal pain
  • Hemorrhoids
  • Giardiasis (a parasitic infection; reported in clinical trials, but unlikely directly caused by Fulyzaq)
  • Anxiety
  • Increased alanine aminotransferase (ALT, a liver enzyme)
  • Abdominal distension (bloating)
• Less Common / Other Side Effects (reported in between 1% and 2% of patients or less common):
  • Abdominal pain
  • Acne
  • Constipation
  • Depression
  • Dermatitis
  • Dizziness
  • Dry mouth
  • Dyspepsia (indigestion)
  • Bleeding after defecation
  • Uncomfortable swelling around the anus
  • Bladder pain, frequent urge to urinate, painful urination
  • Muscle stiffness
  • Headaches
  • Fever
  • Insomnia
  • Weakness or unusual tiredness
• Serious Side Effects (Seek immediate medical attention if any of these occur):
  • While not commonly reported for Fulyzaq, any signs of severe allergic reaction (e.g., widespread rash, hives, swelling of the face/lips/tongue/throat, difficulty breathing, wheezing, chest tightness) require immediate medical attention.
  • Signs of liver problems (e.g., dark urine, yellowing skin/eyes, persistent nausea/vomiting, severe stomach pain).
  • Worsening diarrhea that could indicate an unaddressed infection.

It is crucial to report any new, worsening, or concerning symptoms to your healthcare provider immediately.

Careful patient selection and ongoing monitoring are essential when prescribing and using Fulyzaq.

• Rule Out Infectious Diarrhea: This is the most critical warning. Fulyzaq is not indicated for the treatment of infectious diarrhea. Before starting Fulyzaq, healthcare professionals must perform appropriate diagnostic testing to rule out bacterial, viral, or parasitic causes of diarrhea. If infectious etiologies are not considered, there is a significant risk that patients with an underlying infection will not receive appropriate treatment, potentially leading to worsening disease and serious complications.
• HIV/AIDS Specific Use: Fulyzaq is specifically for non-infectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy. Its safety and effectiveness have not been established in patients without HIV/AIDS, or in pediatric patients (those less than 18 years of age).
• Pregnancy and Lactation: Based on animal data, Fulyzaq may cause fetal harm. There are no adequate, well-controlled studies in pregnant women. Therefore, Fulyzaq should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is unknown if Fulyzaq passes into breast milk. Discuss potential risks and benefits with a healthcare professional if you are pregnant, planning pregnancy, or breastfeeding.
• Liver Function: Although increases in bilirubin and liver enzymes have been observed, these are typically mild. However, monitoring liver function may be advisable in patients with pre-existing liver dysfunction.
• Electrolyte Imbalance: While Fulyzaq helps reduce fluid loss, patients with severe or prolonged diarrhea should still be monitored for signs of dehydration and electrolyte imbalance.

Patients should be counselled to seek medical advice if their diarrhea worsens or persists, or if they develop symptoms suggestive of an infection (e.g., fever, bloody stools).

Fulyzaq (crofelemer) is minimally absorbed systemically, which generally limits its potential for systemic drug-drug interactions. However, in vitro studies suggest that crofelemer has the potential to inhibit certain enzymes and transporters within the gut, which could theoretically affect the absorption of other medications, especially those that are substrates for these pathways. Always inform your doctor and pharmacist about all prescription medications, over-the-counter drugs, and supplements you are taking.

• Cytochrome P450 3A4 (CYP3A4) Inhibition (in the gut): In vitro data indicate that crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut lumen. While systemic inhibition is unlikely due to minimal absorption, this could affect the intestinal metabolism or absorption of co-administered drugs that are sensitive CYP3A4 substrates. Patients taking drugs with narrow therapeutic indices that are primarily metabolized by gut CYP3A4 (e.g., some antiretrovirals, certain benzodiazepines, statins) should be monitored.
• Transporter Inhibition (MRP2 and OATP1A2): Crofelemer also has the potential to inhibit efflux transporter MRP2 and uptake transporter OATP1A2 in the gut. These transporters play roles in drug absorption and excretion.
• Antiretroviral Therapies (ART): Clinical studies have specifically investigated Fulyzaq’s interaction with commonly used antiretroviral medications. Fulyzaq administration has been shown not to have clinically relevant interactions with drugs like nelfinavir, zidovudine, or lamivudine, meaning it does not appear to significantly impact the efficacy or safety of these crucial ART components. HIV viral load and CD4 counts also did not appear to change significantly during treatment.
• Other Anti-diarrheal Medications: Before starting Fulyzaq, ensure that other anti-diarrheal medications are used as directed by your healthcare provider.

It is always prudent for healthcare providers to review a patient’s complete medication list before prescribing Fulyzaq to identify any potential interactions, particularly for drugs that have high intestinal absorption or narrow therapeutic windows.

The dosage for Fulyzaq is standardized for adult patients with HIV/AIDS experiencing non-infectious diarrhea.

• Recommended Dose: The recommended dose of FULYZAQ is one 125 mg delayed-release tablet taken orally two times a day (BID).
• Administration Time: The tablets can be taken with or without food.
• Tablet Integrity: It is crucial that FULYZAQ tablets are swallowed whole and not crushed or chewed. This ensures the delayed-release mechanism functions correctly, allowing the active ingredient, crofelemer, to be released in the intestines where it exerts its effect.
• Missed Dose: If a dose is missed, patients should take their next dose at the regularly scheduled time. They should not double the dose to compensate for a missed one.
• Duration of Therapy: Fulyzaq is intended for ongoing symptomatic relief, and the duration of treatment will be determined by the treating physician based on the patient’s individual response and continued need for diarrhea management.
• No Dosage Adjustment: No specific dosage adjustments are typically recommended based on age (for adults), or renal or hepatic impairment, given its minimal systemic absorption.

Consistent adherence to the prescribed dosage and administration instructions is vital for the optimal management of non-infectious diarrhea.

Fulyzaq (crofelemer) is a prescription-only medication. It cannot be obtained without a valid prescription from a licensed healthcare professional.

• Medical Diagnosis and Exclusion of Infection: A key requirement for prescribing Fulyzaq is a clear diagnosis of non-infectious diarrhea in an adult patient with HIV/AIDS. This necessitates a comprehensive medical evaluation by a healthcare provider to actively rule out infectious causes of diarrhea before initiating treatment. This initial diagnostic step is critical to prevent the inappropriate use of Fulyzaq in cases where an infection requires specific antimicrobial therapy.
• HIV/AIDS Patient Population: Fulyzaq’s indication is specific to adult patients with HIV/AIDS who are on antiretroviral therapy. Prescribing outside of this population requires careful medical judgment, as safety and efficacy have not been established for other patient groups or diarrhea etiologies.
• Specialty Pharmacy and Prior Authorization: As a specialized medication, Fulyzaq often requires prior authorization from insurance providers. It may be obtained through specialty pharmacies, and its coverage can fall under either medical or pharmacy benefits depending on the patient’s insurance plan. Healthcare providers typically need to submit documentation supporting the medical necessity of the treatment.
• Patient Counseling: Healthcare professionals are responsible for educating patients on the proper administration of Fulyzaq, including emphasizing that tablets must be swallowed whole, the importance of ruling out infection, and recognizing when to seek further medical attention.

Therefore, Fulyzaq is strictly managed under the supervision of a qualified healthcare professional, ensuring its appropriate and safe use within its approved indication.

What is Fulyzaq used for? Treatment of non-infectious diarrhea in HIV/AIDS patients on antiretroviral therapy

2. What is the active ingredient? Crofelemer

3. What drug class does it belong to? Antidiarrheal agent (chloride channel modulator)

4. Is it a controlled substance? No

5. Is it available in generic form? No

6. How is Fulyzaq administered? Orally, as tablets

7. What strengths are available? 125 mg delayed-release tablets

8. What is the usual adult dosage? 125 mg twice daily

9. Can it be used in children? Not approved for pediatric use

10. What are common side effects? Flatulence, stomach pain, increased bilirubin, upper respiratory tract infection

11. Can it cause serious reactions? Rare—severe allergic reaction or worsening diarrhea if infectious cause is present

12. Is it safe during pregnancy? Limited data; use only if benefits outweigh risks

13. Is a prescription required? Yes

14. Is Fulyzaq available in Pakistan? Not widely; may be accessed via HIV specialty programs/import

15. How should it be taken? Swallow tablets whole, with or without food

16. What precautions should be taken during use? Rule out infectious causes of diarrhea before starting therapy

17. What are contraindications? Hypersensitivity to crofelemer or excipients

18. What monitoring is needed during use? Monitor stool frequency and consistency; assess for infectious diarrhea

19. Can it be combined with antiretroviral therapy? Yes—specifically indicated for patients on ART

20. What are similar drugs? Loperamide (Imodium), diphenoxylate/atropine (Lomotil) — though mechanism differs